Clinical trials: Ventilator-Associated Pneumonia (VAP)
Nosocomial Pneumonia (NP), Ventilator-associated Pneumonia (VAP)
A Study Comparing Ceftazidime-Avibactam Versus Meropenem in Hospitalized Adults With Nosocomial Pneumonia
The purpose of the study is to evaluate the effects of Ceftazidime-Avibactam compared to Meropenem for treating hospitalized adults with nosocomial pneumonia including ventilator-associated pneumonia
- Trial name
- NCT01808092
- Testing
- ceftazidim-avibactam (CAZ-AVI, experimental product), meropenem (active comparator)
- Where
- 123 sites in Argentina, Brazil and 24 more
- Volunteers
- 969 people
- Sponsor
- Pfizer
Healthcare-associated Pneumonia (HCAP), Bloodstream Infections (BSI)
Study of Cefiderocol (S-649266) or Best Available Therapy for the Treatment of Severe Infections Caused by Carbapenem-resistant Gram-negative Pathogens
This study is designed to provide evidence of efficacy of cefiderocol in the treatment of serious infections in adult patients caused by carbapenem-resistant Gram-negative pathogens.
- Conditions
- Healthcare-associated Pneumonia (HCAP), Bloodstream Infections (BSI), Hospital Acquired Pneumonia (HAP), Complicated Urinary Tract Infection (cUTI)
- Trial name
- CREDIBLE - CR (NCT02714595)
- Testing
- Cefiderocol, Best Available Therapy
- Where
- 85 sites in United States, Brazil and 14 more
- Volunteers
- 152 people
- Sponsor
- Shionogi
VAP - Ventilator Associated Pneumonia
Ventilator-associated Pneumonia (VAP) Diagnostic Stewardship Trial
This is a prospective pilot/feasibility trial of a bundled diagnostic stewardship intervention at the level of the microbiologic testing pathway in ventilator-associated pneumonia (VAP).
- Trial name
- NCT05176353
- Testing
- VAP diagnostic stewardship bundle
- Where
- United States
- Volunteers
- 4,892 people
- Sponsor
- University of Michigan
Healthcare-associated Pneumonia (HCAP), Hospital Acquired Pneumonia (HAP)
Clinical Study of Cefiderocol (S-649266) for the Treatment of Nosocomial Pneumonia Caused by Gram-negative Pathogens
The primary objective of this study is to compare all-cause mortality at Day 14 in participants receiving cefiderocol with participants receiving the comparator, meropenem, in adults with hospital-acquired bacterial pneumonia…
- Conditions
- Healthcare-associated Pneumonia (HCAP), Hospital Acquired Pneumonia (HAP), Ventilator Associated Pneumonia (VAP)
- Trial name
- APEKS-NP (NCT03032380)
- Testing
- Cefiderocol, Meropenem, Linezolid
- Where
- 119 sites in United States, Belgium and 17 more
- Volunteers
- 300 people
- Sponsor
- Shionogi
Ventilator Associated Pneumonia, Critically Ill
Efficacy Study on Silver-coated ETT Cleaned With a Novel Device
The purpose of this study is to test the efficacy of a novel cleaning device in keeping silver-coated endotracheal tubes free from bacterial colonization.
- Trial name
- NCT02120001
- Testing
- ETT cleaning maneuver
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Massachusetts General Hospital
Endotracheal Extubation, Airway Obstruction
Efficacy Study of a Novel Device to Clean the Endotracheal Tube
The purpose of this study is to evaluate the in-vivo efficacy of a novel device (endOclear) for cleaning the endotracheal tube (ETT) lumen from secretions.
- Conditions
- Endotracheal Extubation, Airway Obstruction, Airway Control, Pneumonia, Ventilator-Associated
- Trial name
- NCT01765530
- Testing
- ETT cleaning maneuver
- Where
- United States
- Volunteers
- 74 people
- Sponsor
- Massachusetts General Hospital
Ventilator-associated Pneumonia
Study of Biotene OralBalance Gel for Oral Care in Critically-Ill Mechanically Ventilated Neonates
The goal of this pilot study is to test the hypothesis that mechanically ventilated infants receiving Biotene OralBalance® gel for oral care would have a reduced intubation time compared to infants receiving oral care placebo.
- Trial name
- NCT01314742
- Testing
- Biotene OralBalance® gel, Sterile Water moisten cotton tipped applicator
- Where
- 2 sites in United States
- Volunteers
- 41 people
- Sponsor
- Wake Forest University Health Sciences
Ventilator-Associated Pneumonia (VAP)
Study of Intravenous Ceftolozane/Tazobactam Compared to Piperacillin/Tazobactam in Ventilator-Associated Pneumonia
This is a Phase 3, multicenter, prospective, randomized, open-label, study to compare the safety and efficacy of intravenous (IV) ceftolozane/tazobactam with that of IV piperacillin/tazobactam in the treatment of…
- Trial name
- NCT01853982
- Testing
- Ceftolozane/Tazobactam, Piperacillin/Tazobactam
- Where
- 19 sites in United States, Australia and 1 more
- Volunteers
- 4 people
- Sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Ventilator Associated Pneumonia
The Duration of Antibiotic Therapy for Early (DATE) Ventilator Associated Pneumonia (VAP): 4 vs. 7 Days
The purpose of this study is to see if the amount of antibiotics given for ventilator-associated pneumonia (VAP) can be decreased in order to reduce the risk of adverse effects associated with antibiotics, while at the same time…
- Trial name
- DATE (NCT05545735)
- Testing
- Standard of Care Antibiotic Therapy
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- University of Miami
Early Ventilator Associated Pneumonia
Duration of Antibiotic Treatment for Early VAP (DATE) Trial
Hypothesis: 4 days of antibiotic therapy, as compared to 8 days, is equally effective and results in decreased antibiotic exposure among surgical ICU patients with early VAP.
- Trial name
- DATE (NCT01994980)
- Testing
- Default 4 days antibiotic therapy
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Denver Health and Hospital Authority